1Serviço de Gastroenterologia, Departamento de Clínica Médica, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
2Cavallieri Medical Diagnostic Imaging Centre, Rio de Janeiro, Brazil
3Serviço de Radiologia, Departamento de Radiologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
4Instituto de Estudos de Saúde Coletiva, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
5D’Or Institute for Research and Education, Rio de Janeiro, Brazil
© Copyright 2019. Korean Association for the Study of Intestinal Diseases. All rights reserved.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
FINANCIAL SUPPORT
This study was supported by grants from Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro-(FAPERJ) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTION
Study conception, in the acquisition, analysis, and interpretation of data, and also in the drafting of the manuscript: Moraes AC. Acquisition, analysis, and interpretation of the data, and participated in the drafting of parts of the manuscript: Moraes G, Araújo AL, Elia C. Conception and design of the study, analyzed and interpreted data, and critically revised the manuscript for important intellectual content: Luiz RR, Carneiro AJ, de Souza HS. All authors gave final approval of the submitted version of the manuscript.
Parameter | USCD | Total (%) |
MRE (%) |
κ-value (95% CI) | P-valuea | |
---|---|---|---|---|---|---|
Normal | Abnormal | |||||
Quiescent CD | Normal | 6 (21.4) | 3 | 3 | 0.146 (–0.214 to 0.512) | 0.410 |
Abnormal | 22 (78.6) | 7 | 15 | |||
Total | 28 (100.0) | 10 (35.7) | 18 (64.3) | |||
Active CD | Normal | 1 (6.7) | 0 | 1 | 0.000 | - |
Abnormal | 14 (93.3) | 0 | 14 | |||
Total | 15 (100.0) | 0 | 15 (100.0) | |||
All CD | Normal | 7 (16.3) | 3 | 4 | 0.200 (–0.134 to 0.527) | 0.549 |
Abnormal | 36 (83.7) | 7 | 29 | |||
Total | 43 (100.0) | 10 (23.2) | 33 (76.7) |
Abdominal ultrasonography with color Doppler (USCD) analysis and magnetic resonance enterography (MRE) were defined as abnormal whenever one or more parameters (thickening, mass, abscess, stricture, fistula, hyperemia) were present. Clinical activity based on the Harvey-Bradshaw Index.
a P-value by chi-square McNemar test.
Parameter | USCD | Total (%) |
MRE (%) |
κ-value (95% CI) | P-valuea | |
---|---|---|---|---|---|---|
Absent | Present | |||||
Thickening | Absent | 11 (25.6) | 5 | 6 | 0.307 (–0.042 to 0.608) | 1.000 |
Present | 32 (74.4) | 5 | 27 | |||
Total | 43 (100.0) | 10 (23.3) | 33 (76.7) | |||
Mass (abscess) | Absent | 43 (100.0) | 42 | 1 | 0.000 | - |
Present | 0 | 0 | 0 | |||
Total | 43 (100.0) | 42 (97.7) | 1 (2.3) | |||
Stricture | Absent | 27 (62.8) | 18 | 9 | 0.337 (0.057 to 0.581) | 0.424 |
Present | 16 (37.2) | 5 | 11 | |||
Total | 43 (100.0) | 23 (53.5) | 20 (46.5) | |||
Fistula | Absent | 42 (97.7) | 37 | 5 | –0.040 (–0.108 to 0.000) | 0.219 |
Present | 1 (2.3) | 1 | 0 | |||
Total | 43 (100.0) | 38 (88.4) | 5 (11.6) | |||
Hyperemia | Absent | 25 (58.1) | 17 | 8 | 0.444 (0.178 to 0.711) | 0.388 |
Present | 18 (41.9) | 4 | 14 | |||
Total | 43 (100.0) | 21 (48.8) | 22 (51.2) |
Characteristics | Value (n=43) |
---|---|
Female sex | 27 (62.79) |
Age (yr) | 46.0 (18–82) |
CD duration (yr) | 11 (1–30) |
Age at diagnosis (yr) | |
A1 (<17) | 1 (2.32) |
A2 (17–40) | 29 (67.44) |
A3 (>40) | 13 (30.23) |
Location | |
L1 (terminal ileum) | 30 (69.76) |
L3 (ileocolon) | 13 (30.23) |
Behavior | |
B1 (nonstricturing & nonpenetrating) | 12 (27.91) |
B2 (stricturing) | 19 (44.18) |
B3 (penetrating) | 12 (27.91) |
Surgery for CD | 19 (44.18) |
Activity index | 3.0 (1–17) |
CRP (mg/L) | 1.67 (0.3–89.0) |
Calprotectin (µg/g) | 250 (18–1,800) |
Immunosuppressive agent | 16 (37.21) |
Anti-TNF-α and immunosuppressive agent | 16 (37.21) |
Anti-TNF-α | 7 (16.28) |
Mesalamine | 2 (4.65) |
Corticosteroid | 2 (4.65) |
Parameter | USCD | Total (%) | MRE (%) |
κ-value (95% CI) | P-value |
|
---|---|---|---|---|---|---|
Normal | Abnormal | |||||
Quiescent CD | Normal | 6 (21.4) | 3 | 3 | 0.146 (–0.214 to 0.512) | 0.410 |
Abnormal | 22 (78.6) | 7 | 15 | |||
Total | 28 (100.0) | 10 (35.7) | 18 (64.3) | |||
Active CD | Normal | 1 (6.7) | 0 | 1 | 0.000 | - |
Abnormal | 14 (93.3) | 0 | 14 | |||
Total | 15 (100.0) | 0 | 15 (100.0) | |||
All CD | Normal | 7 (16.3) | 3 | 4 | 0.200 (–0.134 to 0.527) | 0.549 |
Abnormal | 36 (83.7) | 7 | 29 | |||
Total | 43 (100.0) | 10 (23.2) | 33 (76.7) |
USCD | Sensitivity | Specificity | PPV | NPV | ACC |
---|---|---|---|---|---|
Quiescent CD | 83.3 (60.7–94.2) | 30.0 (10.8–60.3) | 68.2 (47.3–83.6) | 50.0 (18.7–81.2) | 64.3 (45.8–79.3) |
Active CD | 93.3 (70.2–98.8) | - | 100.0 (78.5–100.0) | 0.0 (0.0–79.3) | 93.3 (70.2–98.8) |
All CD | 87.9 (72.7–95.2) | 30.0 (10.8–60.3) | 80.5 (64.9–90.2) | 42.9 (15.8–74.9) | 74.4 (59.7–85.1) |
Parameter | USCD | Total (%) | MRE (%) |
κ-value (95% CI) | P-value |
|
---|---|---|---|---|---|---|
Absent | Present | |||||
Thickening | Absent | 11 (25.6) | 5 | 6 | 0.307 (–0.042 to 0.608) | 1.000 |
Present | 32 (74.4) | 5 | 27 | |||
Total | 43 (100.0) | 10 (23.3) | 33 (76.7) | |||
Mass (abscess) | Absent | 43 (100.0) | 42 | 1 | 0.000 | - |
Present | 0 | 0 | 0 | |||
Total | 43 (100.0) | 42 (97.7) | 1 (2.3) | |||
Stricture | Absent | 27 (62.8) | 18 | 9 | 0.337 (0.057 to 0.581) | 0.424 |
Present | 16 (37.2) | 5 | 11 | |||
Total | 43 (100.0) | 23 (53.5) | 20 (46.5) | |||
Fistula | Absent | 42 (97.7) | 37 | 5 | –0.040 (–0.108 to 0.000) | 0.219 |
Present | 1 (2.3) | 1 | 0 | |||
Total | 43 (100.0) | 38 (88.4) | 5 (11.6) | |||
Hyperemia | Absent | 25 (58.1) | 17 | 8 | 0.444 (0.178 to 0.711) | 0.388 |
Present | 18 (41.9) | 4 | 14 | |||
Total | 43 (100.0) | 21 (48.8) | 22 (51.2) |
USCD parameter | Clinical activity | Sensitivity | Specificity | PPV | NPV | ACC |
---|---|---|---|---|---|---|
Thickening | Quiescent | 77.8 (54.8–91.0) | 50.0 (23.6–76.3) | 73.7 (51.2–88.2) | 55.6 (26.6–81.1) | 67.9 (49.3–82.1) |
Active | 86.7 (62.1–96.3) | - | 100.0 (77.2–100.0) | 0.0 (0.0–65.7) | 86.7 (62.1–96.3) | |
All patients | 81.8 (65.6–91.4) | 50.0 (23.6–76.3) | 84.4 (68.2–93.1) | 45.5 (21.3–72.0) | 74.4 (59.7–85.1) | |
Stricture | Quiescent | 50.0 (23.6–76.3) | 83.3 (60.8–94.2) | 62.5 (30.6–86.3) | 75.0 (53.1–88.1) | 71.4 (52.9–84.7) |
Active | 60.0 (31.3–83.2) | 60.0 (23.1–88.2) | 75.0 (40.9–92.8) | 42.9 (15.8–74.9) | 60.0 (35.7–80.2) | |
All patients | 55.0 (34.2–74.2) | 78.3 (58.1–90.3) | 68.8 (44.4–85.8) | 66.7 (47.8–81.3) | 67.4 (52.5–79.5) | |
Hyperemia | Quiescent | 45.5 (21.3–72.0) | 76.5 (52.7–90.4) | 55.6 (26.6–81.1) | 68.4 (46.0–84.4) | 64.3 (45.8–79.3) |
Active | 81.8 (52.3–94.8) | 100 (51.0–100.0) | 100.0 (70.1–100.0) | 66.7 (30.0–90.3) | 86.7 (62.1–96.3) | |
All patients | 63.6 (42.9–80.3) | 81.0 (60.0–92.3) | 77.8 (54.8–91.0) | 68.0 (48.4–82.8) | 72.1 (57.3–83.2) |
Test | Sensitivity | Specificity | PPV | NPV | ACC |
---|---|---|---|---|---|
Clinical activity | 38.9 (24.8–55.1) | 14.3 (2.6–51.3) | 70.0 (48.1–85.4) | 4.3 (0.8–21.0) | 34.9 (22.4–49.8) |
Calprotectin | 70.0 (52.1–83.3) | 71.4 (35.9–91.8) | 91.3 (73.2–97.6) | 35.7 (16.3–61.2) | 70.3 (54.2–82.5) |
CRP | 40.0 (24.6–57.7) | 75.0 (30.1–95.4) | 92.3 (66.7–98.6) | 14.3 (4.9–34.6) | 44.1 (28.9–60.5) |
Challenges | Major findings |
---|---|
Consistently defining disease activity remains a critical challenge in the follow-up of patients with CD. | The sonographic measurements obtained in this study relatively matched the data generated by magnetic resonance, particularly when considering subjects with clinically active disease. |
Abdominal ultrasonography has been proposed for the detection of morphological alterations and inflammatory activity in patients with CD. | Characteristic abnormalities of CD including intestinal wall thickening, stricture formation, and hyperemia were detected by abdominal USCD analysis with a moderate agreement with magnetic resonance. |
Previous studies focusing on Doppler sonography for evaluating CD activity rendered controversial results. | The results indicate that USCD represents a practical noninvasive and a relative low-cost tool for evaluating patients with ileal or ileocolonic disease, particularly in clinically active CD. |
Values are presented as number (%) or median (range).
Abdominal ultrasonography with color Doppler (USCD) analysis and magnetic resonance enterography (MRE) were defined as abnormal whenever one or more parameters (thickening, mass, abscess, stricture, fistula, hyperemia) were present. Clinical activity based on the Harvey-Bradshaw Index.
Parentheses show lower-upper 95% CI. Magnetic resonance used as a criterion standard. Clinical activity based on the Harvey-Bradshaw Index. USCD, ultrasonography with color Doppler; PPV, positive predictive value; NPV, negative predictive value; ACC, accuracy.
USCD, ultrasonography with color Doppler; MRE, magnetic resonance enterography.
Parentheses show lower-upper 95% CI. Magnetic resonance enterography used as a criterion standard. Clinical activity based on the Harvey-Bradshaw Index. USCD, ultrasonography with color Doppler; PPV, positive predictive value; NPV, negative predictive value; ACC, accuracy.
Parentheses show lower-upper 95% CI. Abdominal ultrasonography with color Doppler (USCD) used as a criterion standard. PPV, positive predictive value; NPV, negative predictive value; ACC, accuracy.
USCD, ultrasonography with color Doppler.